MX347871B - Biomarcadores de citoquina como marcadores predictivos de respuesta clínica para acetato de glatirámero. - Google Patents
Biomarcadores de citoquina como marcadores predictivos de respuesta clínica para acetato de glatirámero.Info
- Publication number
- MX347871B MX347871B MX2013003929A MX2013003929A MX347871B MX 347871 B MX347871 B MX 347871B MX 2013003929 A MX2013003929 A MX 2013003929A MX 2013003929 A MX2013003929 A MX 2013003929A MX 347871 B MX347871 B MX 347871B
- Authority
- MX
- Mexico
- Prior art keywords
- glatiramer acetate
- biomarkers
- human subject
- concentration
- clinical response
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/55—IL-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/555—Interferons [IFN]
- G01N2333/57—IFN-gamma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39196810P | 2010-10-11 | 2010-10-11 | |
| PCT/US2011/055588 WO2012051106A1 (en) | 2010-10-11 | 2011-10-10 | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013003929A MX2013003929A (es) | 2013-07-05 |
| MX347871B true MX347871B (es) | 2017-05-16 |
Family
ID=45938670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013003929A MX347871B (es) | 2010-10-11 | 2011-10-10 | Biomarcadores de citoquina como marcadores predictivos de respuesta clínica para acetato de glatirámero. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US8709433B2 (enExample) |
| EP (1) | EP2627669B1 (enExample) |
| JP (2) | JP2013541010A (enExample) |
| KR (1) | KR20140019296A (enExample) |
| AU (1) | AU2011313842B2 (enExample) |
| BR (1) | BR112013008573A2 (enExample) |
| CA (1) | CA2814500A1 (enExample) |
| EA (1) | EA025780B1 (enExample) |
| ES (1) | ES2602977T3 (enExample) |
| IL (1) | IL225118A (enExample) |
| MX (1) | MX347871B (enExample) |
| NZ (2) | NZ703122A (enExample) |
| PL (1) | PL2627669T3 (enExample) |
| PT (1) | PT2627669T (enExample) |
| WO (1) | WO2012051106A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2405749T1 (sl) | 2009-08-20 | 2013-10-30 | Yeda Research And Development Co., Ltd. | Nizkofrekventna terapija z glatiramer acetatom |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| PT2627669T (pt) | 2010-10-11 | 2016-11-24 | Teva Pharma | Biomarcadores de citocina como biomarcadores preditivos de resposta clínica para acetato de glatirâmero |
| MX2014004309A (es) | 2011-10-10 | 2015-07-06 | Teva Pharma | Polimorfismos de nucleotidos individuales utiles para predecir una respuesta clinica para el acetato de glatiramer. |
| US9617596B2 (en) | 2012-10-10 | 2017-04-11 | Teva Pharmaceutical Industries, Ltd. | Biomarkers predictive for clinical response for glatiramer acetate |
| CN105377308B (zh) | 2013-03-14 | 2019-07-26 | 迈兰公司 | 醋酸格拉替雷响应生物标志物mRNA效力测定 |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| US9995734B2 (en) | 2013-10-24 | 2018-06-12 | Mylan Inc. | Human T cell line assay for evaluating the immunologic identity of glatiramer acetate preparations |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| US20160213633A1 (en) * | 2015-01-28 | 2016-07-28 | Teva Pharmaceutical Industries, Ltd. | Method of inducing anti-glatiramer acetate antibody response |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| SI3506921T1 (sl) | 2016-08-31 | 2023-10-30 | Mapi Pharma Ltd. | Depojski sistemi, ki vsebujejo glatiramer acetat |
| JP7602322B2 (ja) | 2017-03-26 | 2024-12-18 | マピ ファーマ リミテッド | 進行型の多発性硬化症を治療するためのグラチラマーデポシステム |
| WO2020047026A1 (en) * | 2018-08-30 | 2020-03-05 | Essen Instruments, Inc. D/B/A Essen Bioscience, Inc. | Methods for determining concentration of low and high concentration proteins in a single sample |
| WO2025181335A1 (en) * | 2024-02-29 | 2025-09-04 | Grifols Worldwide Operations Limited | Methods of treating a cognitive impairment |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| US5800808A (en) | 1994-05-24 | 1998-09-01 | Veda Research And Development Co., Ltd. | Copolymer-1 improvements in compositions of copolymers |
| US6214791B1 (en) | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| IL119989A0 (en) | 1997-01-10 | 1997-04-15 | Yeda Res & Dev | Pharmaceutical compositions for oral treatment of multiple sclerosis |
| CA2337688C (en) | 1998-07-23 | 2016-04-05 | Yeda Research And Development Co., Ltd. | Treatment of autoimmune conditions with copolymer 1 and related copolymers |
| JP2003521448A (ja) | 1998-07-23 | 2003-07-15 | ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ | 合成ペプチドおよび自己免疫疾患治療のための使用方法 |
| ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| PT2090583E (pt) | 1998-09-25 | 2011-09-14 | Yeda Res & Dev | Polipéptidos relacionados com o copolímero 1 para utilização a título de marcadores de massas moleculares e em terapêutica |
| US6514938B1 (en) | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| AU6281599A (en) | 1998-10-02 | 2000-04-26 | Yeda Research And Development Co. Ltd. | Alternate day administration of copolymer 1 for treating autoimmune diseases |
| WO2000027417A1 (en) | 1998-11-12 | 2000-05-18 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd |
| WO2001052878A2 (en) | 2000-01-20 | 2001-07-26 | Yeda Research And Development Co. Ltd. | The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy |
| ZA200206457B (en) | 2000-02-18 | 2003-08-13 | Yeda Res & Dev | Oral, nasal and pulmonary dosage formulations of copolymer 1. |
| EP1261361B1 (en) | 2000-02-18 | 2006-06-14 | Yeda Research And Development Company, Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 (glatiramer acetate) |
| PL363431A1 (en) | 2000-06-05 | 2004-11-15 | Teva Pharmaceuticals Industries, Ltd. | The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| AU783031B2 (en) | 2000-06-07 | 2005-09-15 | Yeda Research And Development Co. Ltd. | The use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for treating diseases caused or exacerbated by glutamate toxicity |
| WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| EP1459065B1 (en) | 2001-12-04 | 2010-07-28 | Teva Pharmaceutical Industries, Ltd. | Processes for the measurement of the potency of glatiramer acetate |
| EP1429800B1 (en) | 2001-12-06 | 2009-02-11 | Yeda Research And Development Co., Ltd. | Vaccine and use thereof for treatment of amyotrophic lateral sclerosis |
| EP1565486A2 (en) | 2002-11-13 | 2005-08-24 | Apotex Pharmachem Inc. | Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine |
| AU2004203772B2 (en) | 2003-01-07 | 2009-07-16 | Yeda Research And Development Co. Ltd. | Eye-drop vaccine containing copolymer 1 for therapeutic immunization |
| RU2339397C2 (ru) | 2003-01-21 | 2008-11-27 | Йеда Рисерч Энд Дивелопмент Ко.Лтд. | Сор1 для лечения воспалительных заболеваний кишечника |
| EP1603530A1 (en) | 2003-03-04 | 2005-12-14 | Teva Pharmaceutical Industries Limited | Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis |
| PL1638589T3 (pl) | 2003-05-14 | 2014-10-31 | Teva Pharmaceutical Industries Ltd | Terapia kombinowana obejmująca octan glatirameru i mitoksantron do leczenia stwardnienia rozsianego |
| US7812116B2 (en) * | 2003-07-03 | 2010-10-12 | Rush University Medical Center | Immunogenic peptides |
| WO2005030955A1 (ja) | 2003-09-29 | 2005-04-07 | Chugai Seiyaku Kabushiki Kaisha | Nk細胞に発現するタンパク質 |
| WO2005041933A1 (en) | 2003-10-31 | 2005-05-12 | Teva Pharmaceutical Industries, Ltd. | Nanoparticles for drug delivery |
| EP1684797A1 (en) | 2003-11-12 | 2006-08-02 | Yeda Research and Development Co. Ltd. | Vaccine and method for treatment of neurodegenerative diseases |
| US20070244056A1 (en) | 2004-03-03 | 2007-10-18 | Liat Hayardeny | Combination Therapy With Glatiramer Acetate and Riluzole |
| US20090048181A1 (en) * | 2004-09-02 | 2009-02-19 | Schipper Hyman M | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis |
| CA2579656C (en) | 2004-09-09 | 2014-11-04 | Teva Pharmaceutical Industries, Ltd. | Process for preparation of mixtures of polypeptides using purified hydrobromic acid |
| HRP20160455T1 (hr) | 2004-09-09 | 2016-07-15 | Yeda Research And Development Co., Ltd. | Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene |
| ATE440888T1 (de) | 2004-10-29 | 2009-09-15 | Sandoz Ag | Verfahren zur herstellung von glatiramer |
| AU2006211510B8 (en) | 2005-02-02 | 2011-04-21 | Teva Pharmaceutical Industries, Ltd. | Process for producing polypeptide mixtures using hydrogenolysis |
| RS52867B (sr) | 2005-02-17 | 2013-12-31 | Teva Pharmaceutical Industries Ltd. | Kombinovana terapija glatiramer acetatom i razagilinom za lečenje multiple skleroze |
| US20100167983A1 (en) | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| EP1891233A4 (en) | 2005-04-25 | 2010-03-24 | Yeda Res & Dev | MARKERS ASSOCIATED WITH THERAPY EFFECTIVENESS OF GLATIRAMERATE ACETATE |
| US20070059798A1 (en) | 2005-09-09 | 2007-03-15 | Alexander Gad | Polypeptides useful for molecular weight determinations |
| WO2007041245A2 (en) * | 2005-09-29 | 2007-04-12 | Biogen Idec Ma Inc. | Biomarkers for multiple sclerosis and methods of use thereof |
| US20070161566A1 (en) | 2006-01-11 | 2007-07-12 | Teva Pharmaceutical Industries, Ltd. | Method of treating multiple sclerosis |
| US20080118553A1 (en) | 2006-06-12 | 2008-05-22 | Anton Frenkel | Tannate salt form of polypeptide mixtures, their preparation and use |
| DE602007003848D1 (de) | 2006-07-05 | 2010-01-28 | Momenta Pharmaceuticals Inc | Verbessertes verfahren zur herstellung von copolymer-1 |
| EP2171044A1 (en) * | 2007-06-25 | 2010-04-07 | Vertex Pharmceuticals Incorporated | Th-17 cells |
| BRPI0819001A2 (pt) | 2007-11-28 | 2014-10-07 | Teva Pharma | "método para retardar o acesso de esclerose múltipla clinicamente defenitiva em um paciente correndo o risco de desenvolver clinicamente a esclerose múltipla definitiva, método para reduzir a progressão da atividade de doença monitorada por imagem latente de ressonância magnética (mri) em um paciente correndo o risco de desenvolver clinicamente a esclerose múltipla definitiva, método para reduzir a progressão dos sintomas de esclerose múltipla definitiva em um paciente, método para reduzir a freqüência de recidiva em um paciente que experimentou um ataque clínico simples sugestivo de esclerose múltipla e que tem pelo menos uma lesão sugestiva de esclerose múltipla, método para retardar a progressão para a esclerose múltipla clinicamente definitiva em um paciente que apresenta um primeiro evento clínico sugestivo de esclerose múltipla e pelo menos uma lesão sugestiva de esclerose múltipla, uso de acetato de glatiramer e acetato de glatiramer |
| EP2113560A1 (en) * | 2008-04-28 | 2009-11-04 | TXCell | Compositions for treating an arthritic condition |
| EP2335066B1 (en) * | 2008-09-19 | 2016-12-28 | University of Utah Research Foundation | Methods for prediction of multiple sclerosis disease and therapy response |
| US8920373B2 (en) | 2009-07-15 | 2014-12-30 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
| PT2275086E (pt) | 2009-07-15 | 2012-05-18 | Teva Pharma | Formulação de volume reduzido de acetato de glatirâmero e métodos de administração |
| SI2405749T1 (sl) | 2009-08-20 | 2013-10-30 | Yeda Research And Development Co., Ltd. | Nizkofrekventna terapija z glatiramer acetatom |
| US8759302B2 (en) * | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| PT2627669T (pt) | 2010-10-11 | 2016-11-24 | Teva Pharma | Biomarcadores de citocina como biomarcadores preditivos de resposta clínica para acetato de glatirâmero |
| MX2014004309A (es) | 2011-10-10 | 2015-07-06 | Teva Pharma | Polimorfismos de nucleotidos individuales utiles para predecir una respuesta clinica para el acetato de glatiramer. |
| US9617596B2 (en) | 2012-10-10 | 2017-04-11 | Teva Pharmaceutical Industries, Ltd. | Biomarkers predictive for clinical response for glatiramer acetate |
| US20160193276A1 (en) | 2012-12-21 | 2016-07-07 | Teva Pharmaceutical Industries, Ltd. | Transmucosal delivery of glatiramer acetate |
| KR20150111919A (ko) | 2012-12-21 | 2015-10-06 | 테바 파마슈티컬 인더스트리즈 리미티드 | 글라티라머 아세테이트의 경구 경점막 전달 |
| MX2015008754A (es) | 2013-01-04 | 2016-04-11 | Teva Pharma | Caracterizacion de un medicamento relacionado con acetato de glatiramer. |
| CA2903127A1 (en) | 2013-03-12 | 2014-10-09 | Teva Pharmaceutical Industries Ltd. | Rituximab induction therapy followed by glatiramer acetate therapy |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
-
2011
- 2011-10-10 PT PT118331990T patent/PT2627669T/pt unknown
- 2011-10-10 NZ NZ703122A patent/NZ703122A/en not_active IP Right Cessation
- 2011-10-10 US US13/269,913 patent/US8709433B2/en not_active Expired - Fee Related
- 2011-10-10 WO PCT/US2011/055588 patent/WO2012051106A1/en not_active Ceased
- 2011-10-10 KR KR1020137012245A patent/KR20140019296A/ko not_active Ceased
- 2011-10-10 CA CA2814500A patent/CA2814500A1/en not_active Abandoned
- 2011-10-10 BR BR112013008573A patent/BR112013008573A2/pt not_active IP Right Cessation
- 2011-10-10 PL PL11833199T patent/PL2627669T3/pl unknown
- 2011-10-10 JP JP2013533913A patent/JP2013541010A/ja not_active Withdrawn
- 2011-10-10 MX MX2013003929A patent/MX347871B/es active IP Right Grant
- 2011-10-10 EA EA201390543A patent/EA025780B1/ru not_active IP Right Cessation
- 2011-10-10 AU AU2011313842A patent/AU2011313842B2/en not_active Ceased
- 2011-10-10 ES ES11833199.0T patent/ES2602977T3/es active Active
- 2011-10-10 EP EP11833199.0A patent/EP2627669B1/en active Active
- 2011-10-10 NZ NZ609938A patent/NZ609938A/en not_active IP Right Cessation
-
2013
- 2013-03-07 IL IL225118A patent/IL225118A/en not_active IP Right Cessation
-
2014
- 2014-04-11 US US14/250,955 patent/US9063153B2/en not_active Expired - Fee Related
-
2015
- 2015-05-07 US US14/706,843 patent/US9625473B2/en not_active Expired - Fee Related
-
2016
- 2016-05-06 JP JP2016093309A patent/JP2016188214A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140019296A (ko) | 2014-02-14 |
| PL2627669T3 (pl) | 2017-02-28 |
| BR112013008573A2 (pt) | 2016-07-12 |
| EP2627669A1 (en) | 2013-08-21 |
| US20140294899A1 (en) | 2014-10-02 |
| AU2011313842B2 (en) | 2016-12-15 |
| US20150241446A1 (en) | 2015-08-27 |
| WO2012051106A1 (en) | 2012-04-19 |
| EA025780B1 (ru) | 2017-01-30 |
| NZ609938A (en) | 2015-11-27 |
| US9063153B2 (en) | 2015-06-23 |
| US8709433B2 (en) | 2014-04-29 |
| JP2016188214A (ja) | 2016-11-04 |
| CA2814500A1 (en) | 2012-04-19 |
| NZ703122A (en) | 2016-06-24 |
| EA201390543A1 (ru) | 2013-09-30 |
| MX2013003929A (es) | 2013-07-05 |
| US9625473B2 (en) | 2017-04-18 |
| JP2013541010A (ja) | 2013-11-07 |
| ES2602977T3 (es) | 2017-02-23 |
| EP2627669A4 (en) | 2014-04-09 |
| AU2011313842A1 (en) | 2013-05-30 |
| EP2627669B1 (en) | 2016-08-17 |
| IL225118A (en) | 2017-10-31 |
| PT2627669T (pt) | 2016-11-24 |
| US20120121619A1 (en) | 2012-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX347871B (es) | Biomarcadores de citoquina como marcadores predictivos de respuesta clínica para acetato de glatirámero. | |
| HK1213830A1 (zh) | 用於预测醋酸格拉替雷临床反应的生物标志物 | |
| MX2016002987A (es) | Biomarcadores de expresion de genes con sensibilidad a laquinimod. | |
| EA201500219A1 (ru) | Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo | |
| IN2012DN06309A (enExample) | ||
| MX2014016014A (es) | Metodos para determinar eficacia de farmacos usando proteinas asociadas a cereblon. | |
| NZ609493A (en) | Diagnosis and treatments relating to th2 inhibition | |
| EA201491011A1 (ru) | Способы лечения с помощью ингибитора гамма-интерферона | |
| WO2011133668A3 (en) | Methods and compositions for the treatment of cancer | |
| EA201200793A1 (ru) | Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин | |
| EA201400119A1 (ru) | Фармацевтическая композиция, способы лечения и их применение | |
| IN2014MN00333A (enExample) | ||
| EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
| EP2700708A3 (en) | Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination | |
| LT2013018A (lt) | Farmacinė kompozicija, skirta gydyti diabetą ir metabolinius sutrikimus | |
| WO2010031749A9 (en) | Compositions and methods for detecting tlr3 | |
| NZ609567A (en) | Markers of endothelial progenitor cells and uses thereof | |
| WO2014140362A3 (en) | Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(msc) | |
| WO2012075023A3 (en) | Neoantibodies for diagnosing tissue injury | |
| NZ596325A (en) | Biomarker for selecting patients and related methods | |
| WO2014169011A3 (en) | Methods for treating immune diseases | |
| TN2012000607A1 (en) | Method for predicting a therapy response in subjects with multiple sclerosis | |
| EP3153861A3 (en) | Biomarkers for predicting response to a cancer vaccine | |
| BR112014002347A2 (pt) | método in vitro para detecção de predisposição ou de diagnóstico e/ou prognóstico de uma deposição anormal de proteínas da matriz extracelular (ecmp), método para seleção de um composto terapêutico para um paciente e método in vitro para determinar a probabilidade de um paciente afetado com uma infecção viral responder a um tratamento com um agente antiviral e/ou um interferon | |
| BRPI1010512A2 (pt) | "método ex vivo para avaliar a eficácia de um tratamento envolvendo a administração de uma composição imunogênica a um paciente, e, uso de níveis de linfócitos t ativados (cd3 + cd69+) como um biomarcador" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |